Related references
Note: Only part of the references are listed.Systematic Comparison of Peptidic Proteasome Inhibitors Highlights the α-Ketoamide Electrophile as an Auspicious Reversible Lead Motif
Martin L. Stein et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2014)
Anti-leukemic activity and mechanisms underlying resistance to the novel immunoproteasome inhibitor PR-924
Denise Niewerth et al.
BIOCHEMICAL PHARMACOLOGY (2014)
Interferon-γ-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines
Denise Niewerth et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2014)
Structure-Based Design of β1i or β5i Specific Inhibitors of Human Immunoproteasomes
Gerjan de Bruin et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Synthesis and Pharmacology of Proteasome Inhibitors
Andreas Rentsch et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2013)
Inhibitors for the Immuno- and Constitutive Proteasome: Current and Future Trends in Drug Development
Eva Maria Huber et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2012)
Immuno- and Constitutive Proteasome Crystal Structures Reveal Differences in Substrate and Inhibitor Specificity
Eva M. Huber et al.
CELL (2012)
Peptido Sulfonyl Fluorides as New Powerful Proteasome Inhibitors
Arwin J. Brouwer et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
PR-924, a selective inhibitor of the immunoproteasome subunit LMP-7, blocks multiple myeloma cell growth both in vitro and in vivo
Ajita V. Singh et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
Nature of Pharmacophore Influences Active Site Specificity of Proteasome Inhibitors
Michael Screen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome
Francesco Parlati et al.
BLOOD (2009)
A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis
Tony Muchamuel et al.
NATURE MEDICINE (2009)
Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome
Susan D. Demo et al.
CANCER RESEARCH (2007)
Molecular shredders: how proteasomes fulfill their role
M Groll et al.
CURRENT OPINION IN STRUCTURAL BIOLOGY (2003)
Crystal structure of epoxomicin:20S proteasome reveals a molecular basis for selectivity of α′,β′-epoxyketone proteasome inhibitors
M Groll et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2000)